General Medicine
An online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.
$120MSeries B
ParticipantEL
Eli Lilly and Company
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Sep 10, 2026
Eli Lilly and Company is a medicines developer that also finances external innovation and provides laboratory and development resources to early biotechnology companies.
Its Catalyze360 platform combines several ways to work with a startup. Lilly Ventures provides investment; Lilly Gateway Labs provides laboratory facilities and scientific engagement; Lilly ExploR&D provides research and development capabilities.
The platform engages biotechs at the earliest stages across therapeutic areas. Its investment remit extends into new scientific platforms and health technology, giving founders routes to strategic capital and development infrastructure through different parts of Lilly’s external innovation organisation.
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $395.5M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionBigHat Biosciences
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
$75MSeries C
ParticipantThatch
A health-benefits platform that lets employers set healthcare budgets while employees choose insurance and eligible care to fit their needs.
$108MNew funding
ParticipantCircle Pharma, Inc.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
$92.5MSeries E
Participant